Publicação
Equity valuation : Regeneron Pharmaceuticals, Inc.
| datacite.subject.fos | Ciências Sociais::Economia e Gestão | |
| datacite.subject.sdg | 03:Saúde de Qualidade | |
| datacite.subject.sdg | 08:Trabalho Digno e Crescimento Económico | |
| dc.contributor.advisor | Martins, José Carlos Tudela | |
| dc.contributor.author | Custódio, Nelson Miguel Lourencinho | |
| dc.date.accessioned | 2026-06-18T20:43:46Z | |
| dc.date.available | 2026-06-18T20:43:46Z | |
| dc.date.issued | 2026-02-04 | |
| dc.date.submitted | 2025-12-01 | |
| dc.description.abstract | This dissertation aims to deliver an informed investment opinion on Regeneron Pharmaceuticals, Inc. as of 31 December 2025. Regeneron is an American biopharmaceutical company listed on Nasdaq since 1991. Its business strategy of connecting advanced technology with scientific innovation has led to the discovery of several drugs over the past three decades. The collaboration with other biopharmaceuticals to develop and commercialize medicines has accelerated the company’s growth. Today, Regeneron is seen as one of the leading innovators in biologic drugs, particularly within oncology, immunology, and ophthalmology. This dissertation incorporates a review of the literature in equity valuation, an analysis on biopharma and Regeneron’s financial profiles, a detailed DCF model, and a multiples’ analysis. Additionally, the intrinsic values found through relative and fundamental valuations will be compared against professional investment opinions from J.P. Morgan and Wells Fargo to complement the final opinion. The DCF model estimates that Regeneron’s intrinsic share value at the end of 2025 lies within a range of $507 to $1011, with a base-case valuation of $813. Overall, the evidence supports a hold recommendation. Although the company shows a great operational profile with high profitability, the market is already foreseeing it, as the current share price is close to the DCF base case outcome and within the market multiples’ ranges. | eng |
| dc.identifier.other | 6841bf95-bb8b-447c-909e-505996e79b95 | |
| dc.identifier.tid | 204310563 | |
| dc.identifier.uri | http://hdl.handle.net/10400.14/58176 | |
| dc.language.iso | eng | |
| dc.rights.uri | N/A | |
| dc.subject | Equity valuation | eng |
| dc.subject | Discounted cash flow | eng |
| dc.subject | Relative valuation | eng |
| dc.subject | Biopharmaceutical | eng |
| dc.subject | Regeneron | eng |
| dc.title | Equity valuation : Regeneron Pharmaceuticals, Inc. | por |
| dc.type | master thesis | |
| dspace.entity.type | Publication | |
| thesis.degree.name | Mestrado em Finanças |
Ficheiros
Principais
1 - 1 de 1